January 6, 2016 – Virttu Biologics, a biopharmaceutical company pioneering the discovery and development of oncolytic viruses for treating cancer, today announced that Deirdre Gillespie MD, Chief Executive Officer, will present at the Biotech Showcase on Monday, January 11, 2016 in San Francisco. Dr Gillespie will discuss SEPREHVIR®, Virttu’s Phase 2 treatment for cancer, and next generation products.
Details of Virttu’s presentation are as follows:
Event: Biotech Showcase™ 2016 Conference
Date: January 11, 2016
Time: 4:30 p.m. Pacific Time
Location: Room Davidson: Parc 55 San Francisco, 55 Cyril Magnin Street.
About VIRTTU Biologics
VIRTTU’s lead oncolytic product SEPREHVIR® has been administered to over 90 patients ranging from 8 to 84 years with many different types of cancer including brain, melanoma, head and neck cancer, sarcomas, neuroblastoma and mesothelioma (a devastating lung cancer associated with asbestos exposure). In these patients, SEPREHVIR can be administered by the route most suitable for their disease which includes systemic administration by intravenous infusion, direct intratumoral injection, and loco-regional infusion. SEPREHVIR, which the company is interested in partnering for further development, is the first product from an active oncolytic immunotherapy platform technology (SEPREHVEC). VIRTTU’s in-house expertise has led to the development of techniques to rapidly engineer further therapeutic modalities into the SEPREHVIR backbone and VIRTTU now has a promising pipeline of next-generation clinical candidates.
For more information about the Company visit www.VIRTTU.com
Details of Virttu’s presentation are as follows:
Event: Biotech Showcase™ 2016 Conference
Date: January 11, 2016
Time: 4:30 p.m. Pacific Time
Location: Room Davidson: Parc 55 San Francisco, 55 Cyril Magnin Street.
About VIRTTU Biologics
VIRTTU’s lead oncolytic product SEPREHVIR® has been administered to over 90 patients ranging from 8 to 84 years with many different types of cancer including brain, melanoma, head and neck cancer, sarcomas, neuroblastoma and mesothelioma (a devastating lung cancer associated with asbestos exposure). In these patients, SEPREHVIR can be administered by the route most suitable for their disease which includes systemic administration by intravenous infusion, direct intratumoral injection, and loco-regional infusion. SEPREHVIR, which the company is interested in partnering for further development, is the first product from an active oncolytic immunotherapy platform technology (SEPREHVEC). VIRTTU’s in-house expertise has led to the development of techniques to rapidly engineer further therapeutic modalities into the SEPREHVIR backbone and VIRTTU now has a promising pipeline of next-generation clinical candidates.
For more information about the Company visit www.VIRTTU.com
